November 14, 2017
Kiran Musunuru, MD, PhD, MPH
ANAHEIM, Calif. — Low levels of four specific metabolites were found to be associated with risk for incident CHD, according to new research from the BiomarCaRE consortium presented at the American Heart Association Scientific Sessions.
The new findings “demonstrate the value of metabolomics for biomarker discovery and improved risk stratification,” Tanja Zeller, PhD, professor of genomics and systems biology at Universitäres Herzzentrum Hamburg GmbH in Germany, said during a presentation.
September 26, 2017
Genotype-guided warfarin dosing reduced the combined risk of major bleeding, international normalized ratio of four or more, venous thromboembolism or death among…
In the Journals
August 31, 2017
Drop in risk for CV events corresponded more closely with reduction in apolipoprotein B levels than with reduction in LDL levels, according to a Mendelian randomization…
In the JournalsPerspective
August 21, 2017
Children with homozygous familial hypercholesterolemia who were treated with rosuvastatin in addition to ezetimibe and/or apheresis reduced their LDL safely and…